Course curriculum

    1. Acromegaly - 2Qs (May 2023)

    2. Alcohol consumption and cancer risk (March 2025)

    3. Alcohol use and cancer risk (March 2021)

    4. Alpha-1 reductase inhibitors and prostate cancer (May 2021)

    5. Anal intraepithelial neoplasia and cancer - 3Qs (July 2018)

    6. Basal cell carcinoma - 2Qs (September 2020)

    7. Borderline ovarian tumors - 3Qs (January 2022)

    8. Brain tumors in children (November 2022)

    9. BRCA testing - 3Qs (November 2023)

    10. BRCA1/2 gene testing (July 2022)

    11. Breast cancer - chemoprophylaxis - 3Qs (September 2022)

    12. Breast cancer - chemoprophylaxis - 3Qs (November 2020)

    13. Breast cancer - chemoprophylaxis - 3Qs (July 2019)

    14. Breast cancer in men - 3Qs (May 2019)

    15. Breast cancer in trans adults - 2Qs (September 2022)

    16. Breast cancer - Genitourinary symptoms - 3Qs (January 2019)

    17. Breast cancer - modifiable risk factors (November 2021)

    18. Breast cancer survivors - Chronic side effects - 4Qs (July 2018)

    19. Breast cancer – triple negative - 4Qs (May 2019)

    20. Breast imaging of dense breasts (January 2023)

    21. Cancer and HIV (January 2025)

    22. Cancer-associated anorexia and cachexia (January 2025)

    23. Carcinoid syndrome - 2Qs (November 2023)

    24. Cell-free DNA testing (May 2019)

    25. Cervical adenopathy (May 2023)

    26. Cervical adenopathy - 2Qs (March 2020)

    27. Cervical cancer screening - 2Qs (September 2018)

    28. Chronic lymphocytic leukemia (May 2023)

    29. Chronic lymphocytic leukemia - 5Qs (July 2020)

    30. Classic Hodgkin lymphoma - 5Qs (May 2020)

    31. Colon cancer - screening - 2Qs (March 2024)

    32. Colonic polypectomy - follow-up - 2Qs (January 2024)

    33. Common variable immunodeficiency (March 2022)

    34. Cutaneous squamous cell carcinoma (March 2019)

    35. Dermoscopy - 3Qs (March 2024)

    36. Diethelstibestrol exposure (September 2022)

    37. Endometrial cancer - 5Qs (November 2020)

    38. Endometrial polyps - 2Qs (March 2023)

    39. Esophageal cancer (November 2021)

    40. Esophageal cancer - 5Qs (March 2020)

    41. Essential thrombocythemia - 2Qs (January 2024)

    42. Evaluation of bone metastases (January 2023)

    43. Ewing sarcoma (January 2019)

    44. Gallbladder cancer (January 2022)

    45. Gallbladder polyps - 2Qs (May 2024)

    46. Gallbladder polyps - 2Qs (May 2020)

    47. Gastric cancer (July 2022)

    48. Gestational trophoblastic disease (January 2019)

    49. Hepatocellular carcinoma - 4Qs (January 2022)

    50. Hepatocellular carcinoma - 2Qs (September 2018)

    51. Hereditary non-polyposis colorectal cancer (HNPCC) - 3Qs (March 2025)

    52. High-grade cervical squamous intraepithelial lesion (July 2018)

    53. Hodgkin lymphoma - 2Qs (September 2021)

    54. HPV infection counseling (July 2022)

    55. HPV-related cancers - 3Qs (November 2021)

    56. H. Pylori and cancer - 2Qs (May 2025)

    57. HSIL - management - 2Qs (September 2024)

    58. Hypercoagulable state - 3Qs (November 2024)

    59. Inflammatory bowel disease and risk of colon cancer (January 2020)

    60. Kaposis sarcoma (July 2021)

    61. Localized prostate cancer (July 2019)

    62. Lung cancer - 4Qs (January 2019)

    63. Lung cancer – chemoprophylaxis (May 2025)

    64. Lung cancer in nonsmokers - 3Qs (September 2019)

    65. Lung cancer in persons who never smoked (July 2024)

    66. Lung cancer - screening (September 2022)

    67. Lung cancer screening - 3Qs (November 2021)

    68. Melanoma - 2Qs (July 2019)

    69. Melanoma overview - 2Qs (September 2021)

    70. Melanoma in skin of color - 2Q (September 2021)

    71. Melanoma types - 3Qs (September 2021)

    72. Meningioma (March 2020)

    73. Mesothelioma (July 2021)

    74. Microscopic hematuria (July 2018)

    75. Multiple endocrine neoplasia - 4Qs (January 2022)

    76. Non-Hodgkin lymphoma - 6Qs (May 2022)

    77. Non-lipid statin use - 2Qs (November 2021)

    78. Oral neoplasms - 2Qs (May 2020)

    79. Paget's disease of the breast - 2Qs (September 2021)

    80. Pancreatic cancer -3Qs (March 2021)

    81. Pancreatic cancer screening (January 2020)

    82. Polycythemia vera - 2Qs (January 2024)

    83. Probiotics and cancer prevention (September 2023)

    84. Prostate cancer – chemoprevention (May 2019)

    85. Prostate cancer prevention (May 2024)

    86. Prostate cancer screening - 3Qs (January 2025)

    87. Prostate cancer screening - 4Qs (November 2023)

    88. Prostate cancer - treatment options - 4Qs (September 2020)

    89. Rectal cancer - 5Qs (November 2020)

    90. Seizure and headache in a middle-aged man - 4Qs (November 2019)

    91. Syndrome of inappropriate antidiuretic hormone (SIADH) - 3Qs (November 2021)

    92. Tamoxifen - 2Qs (November 2022)

    93. Testicular cancer (May 2022)

    94. Thyroid cancer - 2Qs (July 2022)

    95. Transgender breast cancer risk and screening (September 2020)

    96. Triple negative breast cancer (September 2021)

    97. Unprovoked venous thrombosis - 4Qs (November 2019)

    98. Venous thromboembolism and malignancy - 2Qs (January 2019)

About this course

  • Free
  • 98 lessons
  • 0 hours of video content